‌

Actions

Action Type

‌
‌

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Overview

Detailed Summary

Indegene Limited is a digital-first life sciences commercialization company, specializing in biopharmaceutical, biotech, and medical device sectors. It combines healthcare domain knowledge with technology to enhance product development and marketing.
The company achieved a significant financial milestone in Q3 FY26 by surpassing $100 million in quarterly revenue for the first time, reflecting over 30% YoY growth.
The successful execution of large AI-driven deals with global pharma leaders indicates Indegene's strategic focus on using Gen AI platforms to transform operations across commercial and medical sectors.
Recent acquisitions of BioPharm and Warn & Co. have diversified and strengthened Indegene’s capabilities in omnichannel and consulting services, enhancing its market position.
Despite challenges, Indegene maintains a robust financial position, with healthy cash reserves and strong cash generation, enabling sustained investment in growth and innovation.

Sector: Healthcare Services
Industry: Healthcare Research, Analytics & Technology
Market Cap: 11,934 Cr
Volatility: Low Risk
P/E Ratio: 29.8
Industry P/E: 56.4
PEG Ratio: 1.2
P/B Ratio: 4.2
52W High: 632.10
52W Low: 414.90

Sales CAGR

1Y: 9.64%
3Y: 9.34%
5Y: 26.73%
10Y: —

Profit CAGR

1Y: 20.79%
3Y: 10.96%
5Y: 46.57%
10Y: —

ROE

TTM: 12.78%
3Y: 19.76%
5Y: 21.33%
10Y: —

ROCE

TTM: 15.61%
3Y: 22.83%
5Y: 25.06%
10Y: —

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Healthcare Services

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
SYNGENE		404.60	17,409 Cr	49.44	3.68	0.29	9.89	11.96	5.38
INDGN		496.00	11,934 Cr	27.18	4.16	0.40	15.56	19.82	12.28
SUVEN		167.10	5,728 Cr	-20.85	7.47	0.00	-75.33	-75.33	-81.41
VIMTALABS		408.05	2,138 Cr	34.83	6.24	0.21	14.59	19.04	13.94
TAKE		46.04	641 Cr	398.23	24.85	0.00	15.55	21.32	4.57
JSTL		64.02	158 Cr	-51.37	2.48	0.00	-9.29	-5.26	-2.47
BI		57.69	144 Cr	-12.50	0.32	0.00	-2.81	0.93	-2.96
Median: 7 Co.	—	167.10	2,138 Cr	27.18	4.16	0.00	9.89	11.96	4.57

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	673	673	677	687	720	756	761	804	942	1,003
Expenses	525	534	548	561	589	608	606	664	783	840
Operating Profit	149	139	129	126	132	148	155	141	160	164
OPM %	22.11	20.61	19.05	18.36	18.30	19.52	20.41	17.48	16.93	16.30
Other Income	13	26	23	21	38	26	22	20	19	-9.50
Interest	12	12	12	4.00	3.20	3.10	3.70	3.80	4.60	7.20
Depreciation	18	19	20	19	20	21	22	23	40	42
Profit Before Tax	132	134	120	124	146	149	152	133	135	105
Tax %	25.32	28.99	26.67	26.11	25.02	21.23	23.47	23.29	23.61	24.17
Net Profit	99	95	88	92	110	118	116	102	103	80
EPS in Rs	—	4.21	3.73	3.77	4.52	4.86	4.80	4.22	4.25	—

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	553	643	966	1,665	2,306	2,590	2,839	2,924
Expenses	511	499	736	1,378	1,910	2,084	2,305	2,363
Operating Profit	42	144	231	287	396	505	534	561
OPM %	7.60	22.34	23.86	17.24	17.18	19.52	18.82	19.18
Other Income	6.55	-40	33	-21	58	79	107	107
Interest	6.25	8.84	6.96	5.96	31	49	22	14
Depreciation	17	19	26	33	60	76	80	82
Profit Before Tax	26	76	231	226	363	459	539	572
Tax %	45.21	34.45	19.78	28.11	26.69	26.58	24.59	23.85
Net Profit	14	50	186	163	266	337	407	435
EPS in Rs	—	—	—	—	—	15.08	16.89	18.13
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	11.75	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	0.31	0.31	0.31	0.35	44	44	48
Reserves	73	-105	324	764	1,020	1,385	2,568
Borrowings	131	483	51	66	503	490	102
Other Liabilities	124	222	220	524	638	627	609
Total Liabilities	329	600	596	1,353	2,204	2,546	3,326
Fixed Assets	104	119	86	138	664	646	678
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	3.60
Investments	0.00	13	0.00	120	614	797	1,290
Other Assets	225	468	510	1,096	926	1,103	1,355
Total Assets	329	600	596	1,353	2,204	2,546	3,326

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	65	22	172	297	130	508	442
Cash from Investing Activity	-18	-18	-79	-160	-893	-327	-683
Cash from Financing Activity	-21	136	-132	233	333	-66	288
Net Cash Flow	25	140	-38	370	-430	114	47

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2024	Apr 2024	May 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
FIIs	0.00%	3.57%	0.00%	3.57%	3.79%	4.82%	5.03%	5.24%	10.05%	11.30%	11.48%	10.27%
DIIs	100.00%	5.34%	100.00%	5.34%	3.84%	3.17%	3.98%	4.96%	7.20%	6.96%	8.07%	8.30%
Public	0.00%	91.10%	0.00%	91.10%	92.37%	92.01%	90.99%	89.80%	82.75%	81.74%	80.45%	81.44%
Total Shareholders	44	4,43,785	82	4,43,785	2,03,599	1,51,440	1,53,789	1,44,708	1,51,997	1,51,809	1,47,182	1,42,119

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Available on Pro Plan